$55.35 -1.2 -2.1%
Last Trade - 25/01/21
| Market Cap | ÂŁ1.65bn |
| Enterprise Value | ÂŁ1.46bn |
| Revenue | ÂŁ63.4m |
| Position in Universe | 2009th / 6623 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.000 | 0.000 | 0.000 | 0.13 | 0.71 | 13.8 | 112.3 | 157.5 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Axonics Modulation Technologies, Inc. is a medical technology company. The Company is focused on the design, development, and commercialization of sacral neuromodulation (SNM) solutions. SNM therapy is primarily used to treat patients with overactive bladder (OAB), fecal incontinence (FI), and urinary retention (UR). Its rechargeable SNM system (r-SNM System) delivers mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of OAB, FI, and UR. It has two clinical studies relating to its r-SNM System: a European study, RELAX-OAB, and a United States pivotal study, ARTISAN-SNM. SNM therapy consists of two phases: an evaluation period, also called the external trial period, which typically lasts a few days to a few weeks, and a permanent implant for those patients who experience a successful external trial period.
| Last Annual | December 31st, 2019 |
| Last Interim | September 30th, 2020 |
| Incorporated | March 2, 2012 |
| Public Since | October 31, 2018 |
| No. of Shareholders: | n/a |
| No. of Employees: | 302 |
| Sector | Healthcare |
| Industry | Healthcare Equipment & Supplies |
| Index | Nasdaq Composite , |
| Exchange | NASDAQ Global Select Market |
| Shares in Issue | 39,809,412 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 26 Technology Dr, IRVINE, 92618-2380, United States |
| Web | https://www.axonicsmodulation.com/ |
| Phone | +1 949 3966322 |
| Contact | () |
| Auditors | BDO USA, LLP |
As of 25/01/21, shares in Axonics Modulation Technologies Inc are trading at $55.35, giving the company a market capitalisation of ÂŁ1.65bn. This share price information is delayed by 15 minutes.
Shares in Axonics Modulation Technologies Inc are currently trading at $55.35 and the price has moved by 82.18% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Axonics Modulation Technologies Inc price has moved by 55.82% over the past year.
Of the analysts with advisory recommendations for Axonics Modulation Technologies Inc, there are there are currently 4 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Axonics Modulation Technologies Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Axonics Modulation Technologies Inc is scheduled to issue upcoming financial results on the following dates:
Axonics Modulation Technologies Inc does not currently pay a dividend.
Axonics Modulation Technologies Inc does not currently pay a dividend.
Axonics Modulation Technologies Inc does not currently pay a dividend.
To buy shares in Axonics Modulation Technologies Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Axonics Modulation Technologies Inc are currently trading at $55.35, giving the company a market capitalisation of ÂŁ1.65bn.
Here are the trading details for Axonics Modulation Technologies Inc:
Based on an overall assessment of its quality, value and momentum, Axonics Modulation Technologies Inc is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Axonics Modulation Technologies Inc are currently priced at $55.35. At that level they are trading at 10.22% discount to the analyst consensus target price of 0.00.
Analysts covering Axonics Modulation Technologies Inc currently have a consensus Earnings Per Share (EPS) forecast of -1.511 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Axonics Modulation Technologies Inc. Over the past six months, the relative strength of its shares against the market has been 21.5%. At the current price of $55.35, shares in Axonics Modulation Technologies Inc are trading at 33.8% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Axonics Modulation Technologies Inc.
Axonics Modulation Technologies Inc's management team is headed by:
Here are the top five shareholders of Axonics Modulation Technologies Inc based on the size of their shareholding:
